Virupaksha Organics IPO Details
MAINBOARD
Virupaksha Organics IPO DRHP (Draft Red Herring Prospectus) has been Filed With SEBI.
The Lead Managers for Virupaksha Organics IPO are crucial for the offering's success. They are responsible for a wide range of tasks, including preparing the company for the public market, managing the regulatory filings, and marketing the IPO to potential investors. The lead manager for this offering is Axis Capital Ltd, SBI Capital Markets Ltd. To assess their past performance and success in previous IPOs, you can view the Lead Manager Performance Summary report.
For detailed information, Refer to the Virupaksha Organics Limited DRHP.
Virupaksha Organics IPO Details
Virupaksha Organics IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
To be announced | |||
Virupaksha Organics IPO Reservation
Promoter Holding
Documents
Virupaksha Organics IPO Valuations
Virupaksha Organics Financial Information
| Period Ended | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
| Assets | 952.48 | 696.69 | 601.76 |
| Total Income | 816.52 | 769.45 | 650.65 |
| Profit After Tax | 78.71 | 73.68 | 43.09 |
| EBITDA | 144.24 | 139.18 | 90.91 |
| NET Worth | 456.62 | 275.31 | 209.71 |
| Reserves and Surplus | 415.87 | 238.44 | 197.96 |
| Total Borrowing | 282.23 | 264.35 | 240.85 |
| Amount in ₹ Crore | |||
About Virupaksha Organics IPO
Incorporated in 1997, Virupaksha Organics is a research-driven Indian pharmaceutical company that makes active pharmaceutical ingredients (APIs), key starting materials (KSMs), and intermediates.
Along with APIs and intermediates, it also provide contract development and manufacturing (CDMO) services to third-party pharma companies. As of March 31, 2025, the company offer 54 products (23 APIs and 31 intermediates) across a wide range of therapeutic areas such as anti-histamines, analgesics, anti-fungals, anti-diabetics, anti-depressants, anti-asthmatics, and more.
It serve over 550 customers in more than 100 countries, including large multinational pharmaceutical companies in the US, Europe, and Japan. Many of its customer relationships span over eight years. The company have also filed 25 drug master files (DMFs) across global markets, including 11 with the USFDA.
The operations are supported by six manufacturing units in Telangana and Karnataka with 223 reactors and a total capacity of 988 KL. The company uses advanced technologies such as flow chemistry, VapourTech reactors, infrared spectroscopy, NMR, mass spectrometry, and x-ray diffraction to maintain product quality and safety.
As of March 31, 2025, the company employed 978 permanent employees.
Competitive strengths
- Comprehensive product portfolio
- Diversified global customer base with long-standing relationships with key customers
- Robust manufacturing units, backed by our strong research and development capabilities
- Experienced promoters and management team
Strength Of Virupaksha Organics IPO
Risk Of Virupaksha Organics IPO
Objectives Virupaksha Organics IPO
1. Funding capital expenditure requirement for capacity expansion at the Expansion Units
2. Prepayment of all or a portion of certain outstanding borrowings availed by our Company
3. General corporate purposes
Company Contact Details
Virupaksha Organics Ltd.
Plot No. B1 & B2, IDA Gandhinagar,
Kukatpally, Medchal, Malkajgiri
Hyderabad, Telangana, 500037
Phone: + 91 4023075816
Email: cs@virupaksha.com
Website: https://virupaksha.com/
Registrar Contact Details
Lead Mangers
Lead Manager Reports
Virupaksha Organics IPO - FAQs
The Virupaksha Organics IPO is a MAINBOARD public issue comprising 0 equity shares with a face value of ₹10 each, aggregating to a total issue size of . The issue price has been fixed at ₹0 per equity share, and the minimum application size is 0 shares.
The IPO opens for subscription on TBA, and closes on TBA.
Kfin Technologies Ltd has been appointed as the registrar to the issue. The equity shares are proposed to be listed on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE).
As of now, the current GMP stands at TBA.